Acorda Therapeutics (ACOR) Tops Q1 EPS by 18c
Tweet Send to a FriendGet Alerts ACOR Hot Sheet
Price: $32.16 --0%
Revenue Growth %: -12.6%
Financial Fact:
Net sales: 64.08M
Today's EPS Names:
CNET, CNTF, ZLC, More
Revenue Growth %: -12.6%
Financial Fact:
Net sales: 64.08M
Today's EPS Names:
CNET, CNTF, ZLC, More
Trade ACOR Now!
Acorda Therapeutics (NASDAQ: ACOR) reported Q1 EPS of $0.36, $0.18 better than the analyst estimate of $0.18. Revenue for the quarter came in at $71.25 million versus the consensus estimate of $70.95 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Best Buy (BBY) Posts Q1 adj.-EPS of 32c; Comps Down 1.1%
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
